Skip to main content
Equibles

GOLDMAN SACHS GROUP INC

Position in MESO — Mesoblast Ltd

CIK 886982 NEW YORK, NY
Back to MESO Full portfolio

Position in MESO

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$5,352,630
-$756,536 QoQ
Shares Held
395,612
-0.4% QoQ
Ownership
0.305%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#4
of 72 holders
Holding Since
Jun 2020
14 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in MESO Over Time

Shares Held

Position Value (USD)

Derivatives in MESO

reported options exposure · as of Sep 30, 2025
CallValue
$1,611,000
CallShares
100,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GOLDMAN SACHS GROUP INC holds $13,181,249,908 across 360 Biotechnology names. MESO ranks #190 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 2,481,761 $1,232,765,138
2 REGN
Regeneron Pharmaceuticals, Inc.
 1,163,191 $725,296,113
3 ROIV
Roivant Sciences Ltd.
 18,556,458 $656,713,046
4 TECH
BIO-TECHNE Corp
 7,343,324 $518,805,838
5 RVMD
Revolution Medicines, Inc.
 2,133,101 $399,487,154
6 MRNA
Moderna, Inc.
 4,671,950 $327,176,656
7 TNGX
Tango Therapeutics, Inc.
 9,980,620 $311,994,180
8 INCY
Incyte Corp
 2,305,782 $261,383,446

All Filings in MESO

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $5,352,630 395,612
2026-03-31 $6,109,166 397,215
2025-12-31 $7,141,134 395,850
2025-09-30 $1,611,000 100,000
2025-09-30 $6,561,280 407,280
2025-06-30 $4,524,413 415,465
2025-03-31 $3,209,144 257,143
2022-12-31 $105,947 36,408
2021-12-31 $264,201 55,042
2021-09-30 $332,503 55,325
2021-06-30 $433,069 57,897
2021-03-31 $465,377 56,273
2020-12-31 $212,920 25,079
2020-09-30 $644,626 34,676
2020-06-30 $2,324,311 204,066